radiation exposure, anxiety, cost, and low accuracy for subjects with benign lesions. Invasive techniques comprise CTguided transthoracic needle and transbronchial biopsies. The invasive techniques might have a risk of pneumothorax, hemorrhage, and a false negative result. 5 Thus, it is clinically imperative to develop new approaches that can accurately distinguish malignant from benign PNs in a safe and cost-effective manner to prevent individuals with benign growths from the expensive and harmful diagnostic procedures, while allowing effective treatments to be immediately initiated for NSCLC.
Analysis of lung tumor-associated molecular changes in body fluids provides a liquid biopsy for safely and costeffectively detecting NSCLC. MicroRNAs (miRNAs) are small noncoding RNA molecules (containing about 22 nucleotides) that function as posttranscriptional regulators of gene expression. 6 Dysregulation of miRNAs plays a crucial role in lung tumorigenesis. [6] [7] [8] [9] Because of their small size and relative resistance to nucleases, miRNAs are highly stable in peripheral plasma which is an easily accessible and rich biological fluid. 9 Plasma miRNAs that are directly released from primary lung tumors or the circulating lung cancer cells might provide circulating biomarkers for lung cancer. 9, 10 For example, we were one of the first to demonstrate that testing the lung tumor-associated miRNAs in plasma could discriminate NSCLC patients from healthy individuals. 8, [11] [12] [13] Numerous miRNAs have been identified as diverse panels of biomarkers, which, however, produce widespread inconsistent results in lung cancer diagnosis. 11 Furthermore, sensitivities and specificities of these plasma miRNA biomarkers are not high enough to be used in the clinical settings for predicting malignancy among indeterminate PNs. 8 Analysis of patients' demographical characteristics and radiological features of PNs on CT images could also discriminate lung cancer from benign growths. [14] [15] [16] [17] [18] For instance, Swensen et al. developed a Mayo Clinic model based on patients' age, smoking status, cancer history, and location, size and shape of nodules, which could identify malignant PNs with an area under the curve (AUC) of 0.83. 14 Similarly, Gould et al. established a different prediction model based on age, smoking history, nodule diameter, and time since quitting smoking, which yielded 0.78 AUC. 15, 16 McWilliams et al. recently developed another two prediction models with 0.89-0.91 AUCs. 17 However, the clinical/radiological featuresbased models also suffered from moderate sensitivity and specificity. [14] [15] [16] [17] [18] [19] Given the intratumoral heterogeneity and clonal selection throughout the course of lung tumorigenesis, the use of either circulating biomarkers or clinical/radiological factors alone might not provide sufficient power for diagnosis of lung cancer. We aimed to determine if integrating plasma miRNA biomarkers with clinical/radiological characteristics could more accurately identify NSCLC among the indeterminate PNs.
Materials and Methods

Patient cohorts and research design
The study protocols were approved by the Institutional Review Boards of the University of Maryland Medical Center (UMMC), the Baltimore VA Medical Center (BVAMC), and Jiangsu Province Hospital of Traditional Chinese Medicine (JPHTCM). Inclusion criteria were current and former smokers who had CT-detected PNs and were between the ages of 55-74. Exclusion criteria included pregnancy or lactation, current pulmonary infection, thoracic surgery within 6 months, radiotherapy to the chest within 1 year, and life expectancy of <1 year. A PN was defined as a solitary, round, or oval lesion in the lung parenchyma in the absence of adenopathy, atelectasis, or pneumonia. We reviewed the medical records for their demographic and clinical variables about age, gender, race, ethnicity, history of cancer, and smoking behavior (smoking history, smoking status, pack years, and number of years since quitting). We also obtained radiographic characteristics of the PNs on CT images, including the maximum transverse size, the visually determined type (nonsolid or ground-glass opacity, part-solid, solid, perifissural, and spiculation), and the location in the lungs. A definitive malignant diagnosis was established and verified based on pathologic examination of tissues obtained via surgery or biopsy. A definitive benign diagnosis was established when a specific benign etiology was confirmed pathologically, or the PNs were clinically and radiographically stable after a 2-year follow-up with multiple examinations. 20, 21 The surgical pathologic staging was determined according to the TNM classification of the International Union Against Cancer with the American Joint Committee on Cancer and the International Staging System for Lung Cancer. 22 Histopathologic classification was determined according to the World Health Organization classification. 23 Altogether, we recruited 135, Tables 1 and 2 and Supporting Information Table 1 , respectively.
Blood collection, plasma preparation and RNA isolation
The blood samples were collected before any treatment regimen. Variability in the blood collection and preparation might have confounding effects on the molecular analysis of the body fluid specimens. Furthermore, qualities of RNA samples are crucial for the accurate and robust measurement of plasma miRNAs. To reduce the variability and bias linked to sampling methods, storage or purification, in the three medical centers we collected blood and prepared plasma using the standard operating protocols (SOPs) developed by The National Cancer Institute Early Detection Research Network (EDRN). 24, 25 Furthermore, the release of contaminating miRNAs in plasma by hemolysis of blood cells such as red blood cells (RBCs) could yield nonspecific results. To avoid the contamination, we prepared plasma from blood within 2 h after the collection as previously described. 11, 26, 27 Moreover, we used RBC lysis solution to maximally reduce the possible contamination from RBCs in plasma. 13, [28] [29] [30] [31] [32] [33] We extracted RNA from plasma by using a protocol with miRNeasy Mini Kit spin column as described in our published work. 8, [11] [12] [13] 26, 27, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] In addition, we analyzed expression levels of RBC-related miRNA (mir-451), myeloid-related miRNA (miR-223), and lymphoid-associated miRNA (miR- 150) in all the RNA samples. The samples that were positive to these blood cells-related miRNAs were excluded from the study. RNA was immediately stored at 280 in a barcoded cryotube until use.
Microarray analysis
The plasma RNA specimens were analyzed for miRNA expressions by using "Exiqon Services" (Exiqon, Denmark) with an established protocol as described in our previous reports. 47, 48 Briefly, 6 lL RNA was reversely transcribed in 30 lL reactions using the miRCURY LNA TM Universal RT miRNA PCR, Polyadenylation and cDNA synthesis kit (Exiqon). cDNA was diluted 1003 and assayed in 10 lL PCR reactions according to the protocol for miRCURY LNA TM Universal RT miRNA PCR. Each miRNA was assayed by qPCR on the miRNA Ready-to-Use PCR, Haman Panels I using ExiLENT SYBRV R Green master mix. Negative controls excluding template from the reverse transcription reaction were performed and profiled like the samples. The amplification was performed in a LightCyclerV R 480 Real-Time PCR System (Roche, San Francisco, CA) in 384 well plates. The amplification curves were made by using quantification cycle (Cq), which was used as a relative value for further quantification of the tested genes. We normalized the resulted data by using the average of assays detected in the samples (average-assay Cq).
Droplet digital PCR (ddPCR)
ddPCR analysis for quantification of miRNAs was done as described in our published studies. 26, 39, 49 Briefly, 1 lL RNA per sample was obtained for RT to produce cDNA by TaqMan miRNA RT Kit (Applied Biosystems, Foster City, CA) and specific primers for each gene. A 20 lL reaction mixture containing 5 lL of cDNA solution, 10 lL Supermix, 1 lL of Taqman primer/probe mix was loaded into a cartridge with droplet Generation oil (Bio-Rad, Hercules, CA) and then placed into the QX100 Droplet Generator (Bio-Rad). The generated droplets were transferred to a 96-well PCR plate. PCR amplification was carried on a T100 thermal cycler (Bio-Rad). ddPCR was a direct method for quantitatively measuring nucleic acids. 39 The number of positive reactions, together with Poisson's distribution, were used to produce a straight and high-confidence measurement of the original target concentration. 28 Therefore, ddPCR could absolutely quantify targeted nucleic acid sequences without requiring external calibrators or endogenous controls (genes). 26, 28, 29 The plate was loaded on Droplet Reader (Bio-Rad), by which copy number of each miRNA per mL PCR reaction mixture was directly determined. All assays were performed in triplicates. Furthermore, two interplate controls and one notemplate control were carried along in each experiment. The no template control for RT was RNease free water instead of RNA sample input, and no template control for PCR was RNease free water instead of RT products input. 
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Statistical analysis
To identify plasma miRNAs that were differentially expressed in patients with malignant versus benign PNs, we expected the acceptable number of false positives to be 1.0, fold difference between cases and controls at 2.0, standard deviation of the gene measurements on the base-two logarithmic scale at 0.7, and desired power at 80%. Given 375 miRNAs included in the array, at least 15 specimens for each type of the patients were required to achieve the statistical criteria. Furthermore, based on one-sample with binomially distributed outcomes, we needed 45 cases from each group at 5% significant level with 80% power to discover and validate a panel of biomarkers or classifier for predicting malignant PNs. For analysis of microarray data, we performed an unpaired unequal variance t test with Benjamini-Hochberg correction 30 to identify differentially expressed miRNAs in plasma of patients with malignant versus benign PNs. We used univariate analysis to determine which of plasma miRNAs and clinical and radiological variables were associated with malignant PNs. The significantly associated factors were then analyzed by using multivariate logistic regression models with constrained parameters as in least absolute shrinkage and selection operator (LASSO) based on receiver-operator characteristic (ROC) curve to identify an optimal panel of miRNA biomarkers and construct a classifier for malignant PNs. The optimal cutoff value was generated using the Youden index. 31 The 95% confidence intervals in the ROC plot for proportions were estimated. To compare the performance of the classifier with that of the plasma biomarkers and the Mayo Clinic model, 14 we used the method of Hanley and McNeil with the area under an ROC curve (AUC) analysis. 32 The classifier was blindly validated in two additional sets of patients by comparing the calculated results with final clinical diagnosis and the AUCs.
Results
Identifying differentially expressed miRNAs in plasma of patients with malignant versus benign PNs
Of the 375 miRNAs embodied on the miRNA array, 282 (75.2%) showed a <35 Cq value in all plasma specimens of 36 patients with either malignant (18) or benign (18) PNs. Furthermore, the miRNA expression levels measured by using the microarray in the replicates of each sample were highly correlated (all p < 0.0001). Therefore, the 282 miRNAs were reliably measurable in plasma of the patients with PNs. Among the miRNAs, 11 (miRs-21-5p, 2103a-3p, 2126-3p, 2135a-5p, 2145-5p, 2141-3p,-193 b-3p, 2200 b-3p, 2205-5p, 2210 and 2301 b) exhibited >2.0 fold-changes with a p < 0.05 in plasma of patients with malignant versus benign PNs (Supporting Information Table 2 ). Of the 11 miRNAs, nine (miRs-21-5p, 2103a-3p, 2126, 141-3p,-193 b-3p, 2205-5p, 210 and 2301 b) had a higher expression level, whereas three (miRs-135a-5p, 145-5p and 2200 b-3p) displayed a lower level in plasma of patients with malignant versus benign PNs (all p < 0.05).
Validating the changes of the plasma miRNAs, and developing miRNA biomarkers for malignant PNs
The changes of 11 malignant PN-related plasma miRNAs identified by the microarray should be validated using a different and reliable technique. 13 We demonstrated that ddPCR was a more sensitive technique with greater precision and reproducibility to detect expression of miRNAs in plasma than did the conventional reverse transcription PCR (RT-PCR). 26, 39 Moreover, ddPCR could absolutely and precisely determine copy number of miRNAs without the need of an internal control gene, such as U6. Therefore, we used ddPCR to assess changes of the 11 miRNAs in 135 plasma samples of the UMMC cohort. Each well of the plasma samples contained at least 10,000 droplets. By contrast, no product was synthesized in the negative control samples. Thus, the plasma samples were successfully "read" for the absolute quantification of the 11 miRNAs by using a reliable and accurate assay. ddPCR analysis showed that all the 11 miRNAs displayed a significantly different level in plasma samples of patients with malignant PNs versus individuals with benign diseases (all p < 0.05). Furthermore, the miRNAs had consistent changes detected by ddPCR in the same direction as in the microarray analysis: nine displayed a higher expression level, whereas three exhibited a lower level in plasma of subjects with malignant versus benign PNs (Table 3) . To determine the diagnostic values of the plasma miRNAs, ROC and the AUCs were calculated by using the copy number of each miRNA in the UMMC cohort of 135 patients. The individual miRNAs exhibited AUC values of 0.57-0.82 in distinguishing malignant from benign PNs (Table 3) . We used logistic regression models with constrained parameters as in LASSO based on ROC criterion to identify and optimize a panel of miRNA biomarkers. The three miRNAs, miRs-126, 210, and 205-5p are selected as the best biomarkers (all p < 0.001). Combined use of the three miRNAs produced 0.87 AUC for distinguishing malignant from benign PNs. Furthermore, Pearson correlation analysis indicated that the estimated correlation among expression levels of the three miRNAs in plasma was low (all p > 0.05), implying that the diagnostic values of the miRNAs were complementary to each other. Subsequently, combined use of the three miRNAs generated a sensitivity of 81.2% and a specificity of 86.4% (Fig. 1a) . Moreover, including other miRNAs in the model did not improve the accuracy for the identification of malignant PNs. The logistic model had no statistically significant association with histological type and stage of the NSCLC, and patients' age, gender, ethnicity, and smoking history (all p > 0.05).
Developing a classifier by integrating the biomarkers and radiographic features of PNs for identifying malignant PNs
Although showing promise, the 81.2% sensitivity and 86.4% specificity of the three miRNA biomarkers used together are not sufficient in the clinic for distinguishing malignant from Tumor Markers and Signatures benign PNs. We used univariate analysis to determine which of clinical and radiological variables were associated with malignant PNs in 135 patients of the UMMC cohort. History of cancer and smoking pack-years of the patients, the diameter, spiculation, and upper lobe location of the PNs were associated with malignant PNs (Table 4) . We then used logistic regression models with constrained parameters as in LASSO based on ROC criterion to eliminate the large number of the parameters to construct a classifier including: miRs-205-5p and 126, and diameter of PN. The classifier had 0.95 AUC in distinguishing malignant from benign PNs (Fig. 1b) . Adding other miRNAs and imaging/clinical variables in the classifier did not improve the performance for predicting malignant PNs. Furthermore, prediction models based on parameters of PN on CT images and clinical characteristics of smokers have been developed for predicting the probability of malignant PNs, [14] [15] [16] [17] of which, the Mayo Clinic model is a commonly used one. We applied the Mayo Clinic model 14 in the same set of 135 patients for predicting lung cancer by using the equation. The Mayo Clinic model produced an AUC of 0.82 (Fig. 1c) , a similar value as shown in the previous reports. [14] [15] [16] The direct comparison showed that the classifier had a significantly higher AUC value (0.95) compared with the Mayo Clinic model (0.82) and the panel of three biomarkers (0.87) used alone (all p < 0.05) in the same set of patients (Figs. 1ac) . As a result, our classifier yielded 89.9% sensitivity and 90.9% specificity for diagnosis of malignant PNs, which were also significantly higher compared with those of the Mayo Clinic model (75.4% sensitivity and 80.3% specificity) and the biomarkers (81.2% sensitivity and 86.4% specificity) (all p < 0.05) (Figs. 1ac) . Moreover, the classifier did not exhibit statistical differences of sensitivity and specificity between histological types and stages of NSCLC (p > 0.05).
Validating the classifier for differentiating malignant from benign PNs in two independent cohorts of patients with PNs
The three miRNAs (miRs-126, 210 and 205-5p) were analyzed for the expression levels in plasma of both BVAMC and JPHTCM cohorts. The three miRNAs showed a similar change pattern in the two independent cohorts as in the UMMC cohort, providing additional evidence that the plasma miRNAs could be reproducibly measured. The classifier produced 0.94 AUC with a sensitivity of 88.9% and a specificity of 90.5% for diagnosis of malignant PNs in BVAMC cohort (Table 5 ). The classifier produced higher sensitivity and specificity than did the panel of the biomarkers (80.9% sensitivity and 85.7% specificity) and the Mayo Clinic model (74.6% sensitivity and 79.4% specificity) (all p < 0.05) ( Table 5 ). The classifier was further validated in an external set of 98 patients with PNs (the JPHTCM cohort) recruited in China for the diagnostic value in a blinded fashion. The classifier created an AUC of 0.94 with a sensitivity of 87.8% and a specificity of 89.8% for detection of malignant PNs. Furthermore, the classifier had higher sensitivity and specificity (87.8% sensitivity and 89.8% specificity) for detection of malignant PNs than did the panel of the biomarkers (81.6% sensitivity and 85.7% specificity) and the Mayo Clinic model (73.5% sensitivity and 75.5% specificity) (Table 5 ) (all p < 0.05). Taken together, the results created from the extensive validations confirmed the potential of the classifier for estimating the probability of lung cancer among indeterminate PNs.
Discussion
Numerous plasma miRNA biomarkers have been searched by detecting circulating miRNAs directly released from primary tumors or the circulating lung cancer cells, but have limited success, due to several challenges 9 : (i), the release of contaminating miRNAs in plasma by hemolysis of blood cells always produces a low specificity with inconsistent results for cancer diagnosis. (ii), since the amount of miRNAs directly derived from primary tumors in plasma is very low and further 'diluted' in a background of normal miRNAs, 9,10 some cancer cell derived-miRNAs presenting at very low abundance in plasma are undetectable by RT-PCR, producing a very poor sensitivity for cancer detection. 28 (iii), no standard is robustly and reproducibly quantified by ddPCR. Because ddPCR could reliably and sensitively measure the vital miRNAs that were not previously detectable in plasma using RT-PCR, our newly developed three miRNA biomarkers are not the same as the previous ones developed by using RT-PCR. 8, 11, 13, 27 However, although using only three miRNAs, the logistic model has a higher specificity compared with a circulating miRNA signature composed by reciprocal ratios among 24 miRNAs (87% vs. 81%) for identifying lung cancer. 33 Previously, some models based on the clinical/radiological variables have shown the potential for predicting malignant PNs. 14, 16, 17 Our present study confirms the previous findings that the clinical and radiological variables could be predictors for malignant PNs. However, the moderate sensitivity and specificity of these models limits the application in the clinical settings. 14, 16 We reason that integrating plasma biomarkers with radiological/clinical characteristics might have a synergistic effect for identifying NSCLC among the indeterminate PNs. Indeed, by integrating the plasma biomarkers with radiological characteristics, we develop a classifier for distinguishing malignant from benign PNs. Although this simple classifier comprises only two biomarkers and one radiological variable of PNs, it has higher sensitivity and specificity compared with the panel of biomarkers or the Mayo Clinic model used alone. Furthermore, the performance of the classifier developed in White Americans and African Americas is confirmed in a geographically independent cohort (Chinese population), further implying the usefulness for detection of NSCLC among indeterminate PNs. In addition, the classifier with a simple equation and a single cut-off value would offer a convenient analytic means in the laboratory settings for the classification of malignant from benign PNs.
The areas for improvement do exist in the current study. A screening assay directed at a malignancy with an incidence 5% should have a sensitivity exceeding 95% when the specificity is 95%, and vice versa. The incidence of lung cancer in heavy smokers is <3%, while LDCT has 90% sensitivity and only 61% specificity, producing a high false positive rate. Only the approaches with >95% specificity and appropriate sensitivity for identifying malignant PNs could supplement LDCT lung cancer screening. Although showing promise, our developed classifier with 89% sensitivity and 90% specificity does not hold the required performance. The two plasma miRNA biomarkers in the classifier were developed from the limited number of miRNAs identified by microarrays, however, by which other important lung cancerassociated miRNAs might not been included. We are using high-throughput next-generation sequencing to directly analyze plasma samples of patients with either malignant or benign PNs to identify new miRNA biomarkers for lung cancer. The performance of this classifier could be further improved by adding the new plasma miRNA biomarkers that are more specific to malignant PNs. Furthermore, the radiological features used in the study are obtained through the conventional imag analsyis that is based on subjective observation and limited to the measurements of nodule size in one dimension. Radiomics, an emerging technique extracting a large number of quantitative features from medical images automatically, provides a more detailed quantification of tumor phenotypic characteristics that have diagnostic value. In the future, we intend to incorporate the molecular biomarkers, radiomic features of nodules, and clinical characteristics of smokers to develop a classier that could more accurately and conveniently identify lung cancer among the indeterminate PNs.
In summary, we have for the first time developed a simple classifier by integrating plasma biomarkers with radiological characteristics that could identify lung cancer among indeterminate PNs. Future use of the classifier by sparing individuals with benign growths from the harmful diagnostic procedures, while allowing effective treatments to be immediately initiated for NSCLC, would complement LDCT for the early detection of lung cancer. Nevertheless, undertaking a prospective study to further validate the classifier for lung cancer in a large population-based LDCT screening positive setting among heavy smokers is required.
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